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Treatment with Convalescent Plasma  
for Influenza A (H5N1) Infection
To the Editor: A previously healthy 31-year-old 
male van driver presented to a local clinic in Shen-
zhen, in southern China, on June 7, 2006, with a 
4-day history of a high fever (temperature, 39.9°C), 
chills, and a cough with clear sputum. A chest ra-
diograph obtained on June 9 revealed large opac-
ities in the lower lobe of the left lung. A reverse-
transcriptase–polymerase-chain-reaction (RT-PCR) 
assay and an isolate from a tracheal aspirate were 
positive for influenza A (H5N1) virus. Treatment 
with 150 mg of oseltamivir twice daily was started 
at 2 a.m. on June 12 (Fig. 1). After 2 days, there was 
increased consolidation in the right lung and only 
slight improvement in the left lung. Quantitative 
RT-PCR revealed a high viral load (1.31×105 copies 
per milliliter) when it was first measured (at 4 a.m. 
on June 13), 26 hours after the patient began to re-
ceive oseltamivir. The viral load continued to in-
crease and was 1.68×105 copies per milliliter by 
10 a.m. on June 14, despite the continuation of os-
eltamivir treatment. Although oseltamivir resis-
tance during the treatment of influenza A (H5N1) 
virus infection has been reported,1 no genetic evi-
dence of resistance to oseltamivir was observed in 
our patient.
Because a predominant H5N1 influenza variant 
(clade 2.3) had been identified in poultry across 
southern China,2 convalescent plasma was ob-
tained from a patient from Anhui province who 
had recovered from H5N1 infection in February 
2006. Three 200-ml transfusions of convalescent 
plasma (neutralizing antibody titer, 1:80 dilution) 
33p9
40.5
Te
m
pe
ra
tu
re
 (°
C
)
V
ir
al
 L
oa
d 
(r
el
at
iv
e 
co
py
 n
o.
×
10
0/
m
l)
39.5
40.0
39.0
38.5
37.5
37.0 0
1800
1600
1400
1200
1000
800
600
400
200
38.0
0.0
June 5
June 15
2 a.m.
June 12
2 a.m.
July 1
June 3
onset
7 9 11 13 17 19 21 23 25 27 29
Viral load
Body temperature
Days
AUTHOR:
FIGURE:
JOB: ISSUE:
4-C
H/T
RETAKE
SIZE
ICM
CASE
EMail Line
H/T
Combo
Revised
AUTHOR, PLEASE NOTE: 
Figure has been redrawn and type has been reset.
Please check carefully.
REG F
Enon
1st
2nd
3rd
Guan
1 of 1
10-04-07
ARTIST: ts
35714
Oseltamivir
therapy
Convalescent
plasma therapy
June 14
10 a.m.
June 13
4 a.m.
June 15, 10 a.m.
June 16, 10 a.m.
Figure 1. Influenza A (H5N1) Viral RNA Load in Tracheal Aspirates and the Patient’s Response to Treatment.
The green line represents the patient’s body temperature, and the purple line represents the viral load. The orange 
line represents the beginning of oseltamivir therapy, and the blue line represents the beginning of convalescent 
plasma therapy.
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were given to our patient; one was given at 2 a.m. 
on June 15, one at 10 a.m. on June 15, and one at 
10 a.m. on June 16. After the first transfusion, the 
patient’s viral load was reduced by a factor of ap-
proximately 12 (from 1.68×105 to 1.42×104 copies 
per milliliter) during the first 8 hours (from 2 a.m. 
to 10 a.m. on June 15) and was undetectable 
within 32 hours. A radiograph obtained on June 
15 showed reduced density of the pulmonary le-
sions in the left lobe; however, consolidation in 
the right lower lobe had progressed. Oseltamivir 
treatment was stopped at 10 a.m. on June 16 be-
cause of persistently negative results on RT-PCR. 
The patient recovered and was discharged on Au-
gust 4.
We performed tests of neutralizing antibodies 
against A/chicken/Hong Kong/282/2006, a virus 
closely related to A/Shenzhen/406H/2006. The neu-
tralizing-antibody titer was negative on June 14 
and 15, then it rose steadily and was between 1:40 
and 1:80 by June 20. This increase may have been 
the result of both the treatment with convalescent 
plasma and the patient’s own humoral immune 
response, since the neutralization antibodies were 
maintained at this level thereafter. H5N1 viruses 
were successfully isolated from tracheal aspirates 
from both this patient and the plasma donor. 
A subsequent analysis revealed that the virus from 
the plasma donor and the current patient were 
closely related genetically, with greater than 99% 
homology in their hemagglutinin genes. Both vi-
ruses were Fujian-like H5N1 variants that have 
been predominant in poultry and have caused 
other human infections in southern China since 
2005 (e.g., A/Guangxi/1/2005, A/Zhejiang/16/2006, 
and A/chicken/Hong Kong/282/2006).2 Our results 
indicate that passive immunotherapy may be a 
viable option for the treatment of influenza A 
(H5N1) infection. Therefore, the development of 
passive immunotherapy with humanized monoclo-
nal or polyclonal antibodies warrants further con-
sideration.3-5
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Tissue-Engineered Blood Vessel for Adult  
Arterial Revascularization
To the Editor: A material that will approach the 
efficacy of native vein has been widely sought.1 
Using autologous cells and a technique termed 
sheet-based tissue engineering, we were able to 
produce autologous tissue-engineered blood ves-
sels with physiologic mechanical properties.2 No 
synthetic or exogenous materials were used; in-
stead, the vessels were created with the use of au-
tologous fibroblasts and endothelial cells harvested 
from a small biopsy specimen of skin and super-
ficial vein. Here we report on the preliminary use 
of these tissue-engineered blood vessels in an adult 
arterial model.
Ten patients receiving hemodialysis whose ar-
teriovenous shunts were failing were enrolled in 
this study. The subjects had typical risk factors for 
end-stage renal disease, including previously failed 
dialysis-access grafts, diabetes, controlled hyper-
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